Evaluation of the architect Epstein-Barr Virus (EBV) viral capsid antigen (VCA) IgG, VCA IgM, and EBV nuclear antigen 1 IgG chemiluminescent immunoassays for detection of EBV antibodies and categorization of EBV infection status using immunofluorescence assays as the reference method

Clinical and Vaccine Immunology

Volumn 21, Issue 5, 2014, Pages 684-688

  Corrales, Isabel ^a   Giménez, Estela ^a   Navarro, David ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 2; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS CAPSID ANTIGEN; CAPSID PROTEIN; EBV-ENCODED NUCLEAR ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANTIBODY DETECTION; ARTICLE; CHEMOLUMINESCENCE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE; MICROPARTICLE ENZYME IMMUNOASSAY; NONHUMAN; PRIMARY INFECTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROLOGY; BLOOD; CHILD; COMPARATIVE STUDY; DIAGNOSTIC TEST; DIAGNOSTIC USE; EPSTEIN-BARR VIRUS INFECTIONS; EVALUATION STUDY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; INFANT; LUMINESCENCE; MALE; PRESCHOOL CHILD; PROCEDURES;

ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; CHILD; CHILD, PRESCHOOL; DIAGNOSTIC TESTS, ROUTINE; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFANT; LUMINESCENT MEASUREMENTS; MALE; SENSITIVITY AND SPECIFICITY;

EID: 84899705329     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00104-14     Document Type: Article

References (17)

1. Hess RD. 2004. Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J. Clin. Microbiol. 42: 3381-3387. http://dx.doi.org/10.1128/JCM.42.8.3381-3387.2004. (Pubitemid 39045655)
2. Bravo D, Muñoz-Cobo B, Costa E, Clari MA, Tormo N, Navarro D. 2009. Evaluation of an immunofiltration assay that detects immunoglobulin M antibodies against the ZEBRA protein for the diagnosis of Epstein-Barr virus infectious mononucleosis in immunocompetent patients. Clin. Vaccine Immunol. 16:885-888. http://dx.doi.org/10.1128/CVI.00123-09.
3. Meza LD, Sancho-Tello S, Muñoz-Cobo B, Costa E, Bravo D, Pazos JM, Corrales I, Marcano X, Tohalino M, Navarro D. 2012. Performance of an immunofiltration assay detecting IgM antibodies against ZEBRA and viral capsid p18 proteins (Immunoquickfiltration EBV M) for the diagnosis of heterophile antibody-negative primary Epstein-Barr virus infection in children. J. Clin. Virol. 53:270-271. http://dx.doi.org/10.1016/j.jcv.2011.12.008.
4. de Ory F, Guisasola ME, Sanz JC, Garcia-Bermejo I. 2011. Evaluation of four commercial systems for the diagnosis of Epstein-Barr virus primary infections. Clin. Vaccine Immunol. 18:444-448. http://dx.doi.org/10.1128/CVI. 00486-10.
5. Gärtner BC, Gärtner BC, Hess RD, Bandt D, Kruse A, Rethwilm A, Roemer K, Mueller-Lantzsch N. 2003. Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method. Clin. Diagn. Lab. Immunol. 10:78-82. http://dx.doi.org/10. 1128/CDLI.10.1.78-82.2003. (Pubitemid 36133833)
6. Binnicker MJ, Jespersen DJ, Harring JA, Rollins LO, Beito EM. 2008. Evaluation of a multiplex flow immunoassay for detection of Epstein-Barr virus-specific antibodies. Clin. Vaccine Immunol. 15:1410-1413. http://dx.doi.org/10.1128/CVI.00082-08.
7. Debyser Z, Reynders M, Goubau P, Desmyter J. 1997. Comparative evaluation of three ELISA techniques and an indirect immunofluorescence assay for the serological diagnosis of Epstein-Barr virus infection. Clin. Diagn. Virol. 8:71-81. http://dx.doi.org/10.1016/S0928-0197(97)00014-7. (Pubitemid 27283266)
8. Klutts JS, Ford BA, Perez NR, Gronowski AM. 2009. Evidence-based approach for interpretation of Epstein-Barr virus serological patterns. J. Clin. Microbiol. 47:3204-3210. http://dx.doi.org/10.1128/JCM.00164-09.
9. Lupo J, Germi R, Semenova T, Buisson M, Seigneurin JM, Morand P. 2012. Performance of two commercially available automated immunoassays for the determination of Epstein-Barr virus serological status. Clin. Vaccine Immunol. 19:929-934. http://dx.doi.org/10.1128/CVI.00100-12.
10. Kreuzer C, Nabeck KU, Levy HR, Daghofer E. 2013. Reliability of the Siemens Enzygnost and Novagnost Epstein-Barr virus assays for routine laboratory diagnosis: agreement with clinical diagnosis and comparison with the Merifluor Epstein-Barr virus immunofluorescence assay. BMC Infect. Dis. 13:260. http://dx.doi.org/10.1186/1471-2334-13-260.
11. De Paschale M, Agrappi C, Manco MT, Mirri P, Viganò EF, Clerici P. 2009. Seroepidemiology of EBV and interpretation of the "isolated VCA IgG" pattern. J. Med. Virol. 81:325-331. http://dx.doi.org/10.1002/jmv. 21373.
12. Nystad TW, Myrmel H. 2007. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis. J. Clin. Virol. 38:292-297. http://dx.doi.org/10.1016/j.jcv.2007.01.006. (Pubitemid 46413995)
13. Gulley ML, Tang W. 2008. Laboratory assays for Epstein-Barr virus-related disease. J. Mol. Diagn. 10:279-292. http://dx.doi.org/10.2353/jmoldx.2008. 080023. (Pubitemid 352022708)
14. Odumade OA, Hogquist KA, Balfour HH, Jr. 2011. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin. Microbiol. Rev. 24:193-209. http://dx.doi.org/10.1128/CMR.00044-10.
15. García T, Tormo N, Gimeno C, Navarro D. 2008. Assessment of Epstein-Barr virus (EBV) serostatus by enzyme immunoassays: plausibility of the isolated EBNA-1 IgG positive serological profile. J. Infect. 57:351-353. http://dx.doi.org/10.1016/j.jinf.2008.07.017.
16. Berth M, Bosmans E. 2009. Acute parvovirus B19 infection frequently causes false-positive results in Epstein-Barr virus- and herpes simplex virus-specific immunoglobulin M determinations done on the Liaison platform. Clin. Vaccine Immunol. 16:372-375. http://dx.doi.org/10.1128/CVI.00380-08.
17. Costa E, Tormo N, Clari MA, Bravo D, Muñoz-Cobo B, Navarro D. 2009. Performance of the Epstein-Barr virus and herpes simplex virus immunoglobulin M assays on the Liaison platform with sera from patients displaying acute parvovirus B19 infection. Clin. Vaccine Immunol. 16:1247-1248. http://dx.doi.org/10.1128/CVI.00142-09.